Keyphrases
Survivors
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
77%
Pediatric
71%
Hematopoietic Cell Transplantation
66%
Graft-versus-host Disease (GvHD)
62%
Post-transplant Lymphoproliferative Disorder
54%
Late Effects
54%
Childhood Cancer Survivors
53%
Childhood Cancer Survivor Study
53%
Confidence Interval
47%
Risk Factors
42%
Children's Oncology Group
41%
Pediatric Patients
37%
Older Adults
35%
Hematopoietic Stem Cell Transplantation
34%
Reduced-intensity Conditioning
34%
Marrow Transplantation
32%
Young Adult Oncology
30%
Acute Lymphoblastic Leukemia
29%
Overall Survival
28%
Hearing Impairment
28%
Pediatric Cancer Patients
26%
Non-Hodgkin Lymphoma
26%
Odds Ratio
25%
Event-free Survival
25%
Methotrexate
25%
Chemotherapy
25%
Transplantation
23%
Pediatric Oncology
23%
Quality of Life
22%
Stem Cell Transplantation
22%
Total Body Irradiation
21%
Unrelated Donor
20%
Young Adult Patients
20%
NCCN Guidelines
20%
Retinoblastoma
20%
Newly Diagnosed
19%
Lung Transplantation
18%
Oncology
18%
Preparative Regimen
17%
Cisplatin
17%
Haematopoietic Stem Cell Transplant Recipients
16%
Solid Organ Transplantation
15%
Allogeneic Transplantation
15%
Reduced Intensity
15%
Solid Cancer
15%
Sudden Sensorineural Hearing Loss (SSNHL)
15%
Nashville
15%
Consensus Conference
15%
Lymphoblastic Lymphoma
15%
Medicine and Dentistry
Pediatrics
91%
Childhood Cancer
91%
Hematopoietic Cell
88%
Adolescence
86%
Cell Transplantation
83%
Oncology
73%
Transplantation
67%
Diseases
58%
Late Effect
47%
Acute Lymphoblastic Leukemia
42%
Posttransplant Lymphoproliferative Disease
41%
Hematopoietic Stem Cell Transplantation
40%
Malignant Neoplasm
38%
Methotrexate
35%
Prevalence
32%
Pediatrics Patient
29%
Overall Survival
29%
Graft Versus Host Reaction
26%
Reduced Intensity Conditioning
25%
Allograft
24%
Non-Hodgkin Lymphoma
23%
Quality of Life
23%
Event Free Survival
21%
Acute Leukemia
20%
Whole Body Radiation
19%
Neoplasm
19%
Odds Ratio
19%
Chronic Graft Versus Host Disease
18%
Solid Malignant Neoplasm
18%
Radiation Therapy
17%
Lung Transplantation
17%
Lymphoblastic Lymphoma
17%
Leukemia
16%
Lymphoma Cell
15%
Solid Organ Transplantation
15%
Drug Megadose
15%
Retinoblastoma
15%
Sickle-Cell Disease
15%
Hematologic Malignancy
15%
Immunosuppressive Treatment
14%
Epstein Barr Virus
14%
Myelodysplastic Syndrome
14%
Acute Myeloid Leukemia
13%
T Cell
13%
Rituximab
12%
Hearing Impairment
12%
Pediatric Cancer
11%
Infection
11%
Long Term Survival
11%
Central Nervous System
11%